UK company launches marine algae product
introducing its blend of Red Marine Algae as a food supplement to
treat bacteria and viruses such as Candida albicans and
Enterococcus faecalis bacteria.
Northern Ireland-based Dolphin Sea Vegetable Company (DSV) is introducing its blend of Red Marine Algae as a food supplement to treat bacteria and viruses such as Candida albicans and Enterococcus faecalis bacteria.
In tests conducted at the University of Galway in the Republic of Ireland, the product, PhycoPLEX, proved effective against viral, bacterial and other microbial pathogens, said the company, and like certain other red marine algaes it can also treat the Herpes and Epstein-Barr viruses.
To facilitate the launch of PhycoPLEX through DSV's online partner Verde Naturals, the company is setting up DSV Nutriceuticals to market its products.
Candida albicans and Enterococcus faecalis are known to be contributing factors in Irritable Bowel Syndrome, a condition with no known remedy. DSV claims that PhycoPLEX is the first natural supplement to show potential in alleviating the symptoms of IBS. The company adds that its 100 per cent natural seaweed formula is of higher quality and more effective than other red marine algaes.
Established in 1993, DSV supplies wildcrafted red marine algae to other manufacturers and carries out research into the pharmacological benefits of seaweeds and algae for various medical, pharmaceutical and health food companies. Both PhycoPLEX and the other DSV product, VerdeRMA, are marketed exclusively by US firm Verde Naturals.
DSV said it is continuing research and development of PhycoPLEX through clinical trials into its immune system function and modulatory action conducted at the University of Ulster, supported by a European Union grant.
